AZENTA Inc. (AZTA) Rating Upgraded to 80% Reflecting Strong Fundamentals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Source: NASDAQ.COM
- Rating Upgrade: AZENTA Inc. (AZTA) saw its rating increase from 0% to 80% based on Joseph Piotroski's investment strategy, indicating a significant improvement in the company's fundamentals and stock valuation, which suggests rising market interest in the stock.
- Industry Position: Operating in the Biotechnology & Drugs sector, AZENTA provides global life sciences solutions that encompass drug development, clinical research, and advanced cell therapies, enhancing its competitive edge in a rapidly growing market.
- Service Diversity: The company's Sample Management Solutions and Multiomics services offer comprehensive cold-chain sample management for pharmaceutical, biotech, and healthcare institutions, improving clients' R&D efficiency and service quality.
- Investment Strategy: Piotroski's strategy screens for high book-to-market stocks while assessing financial health, aiding investors in identifying potential quality investment opportunities, thereby further boosting AZENTA's market recognition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZTA
Wall Street analysts forecast AZTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZTA is 41.83 USD with a low forecast of 31.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 39.000
Low
31.00
Averages
41.83
High
50.00
Current: 39.000
Low
31.00
Averages
41.83
High
50.00
About AZTA
Azenta, Inc. is a provider of life sciences solutions worldwide. The Company provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The Company's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Company's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The Company's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Azenta (AZTA) to Announce Q1 2026 Earnings on February 4, 2026
- Earnings Announcement: Azenta will release its fiscal Q1 2026 earnings on February 4, 2026, before market open, reflecting the company's ongoing growth potential in the life sciences sector.
- Conference Call Details: The company will host a conference call and live webcast at 8:30 AM ET on the same day, allowing analysts and investors to access information directly through Azenta's website, ensuring transparent communication.
- Replay Availability: A replay of the earnings call will be available starting at 8:30 AM ET on February 5, 2026, facilitating access to key information for investors who cannot attend live, thereby enhancing investor relations management.
- Company Overview: Azenta is a leading provider of life sciences solutions globally, focusing on drug development and clinical research, with multiple industry-leading brands, underscoring its significant position in the rapidly evolving biotech market.
Continue Reading
Azenta, Inc. to Announce Q1 2026 Earnings on February 4, 2026
- Earnings Announcement: Azenta, Inc. will announce its fiscal Q1 2026 earnings on February 4, 2026, before market open, reflecting the company's ongoing growth in the life sciences sector.
- Conference Call Details: The company will host a conference call and live webcast at 8:30 AM ET on the same day, allowing analysts and investors to engage directly, enhancing transparency and investor relations.
- Replay Availability: A replay of the earnings call will be available starting at 8:30 AM ET on February 5, 2026, ensuring that investors who cannot attend live can still access critical information.
- Company Overview: Azenta is a leading provider of life sciences solutions globally, focusing on drug development and clinical research, committed to accelerating impactful breakthroughs and therapies to market, showcasing significant industry influence.
Continue Reading